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OBJECTIVE — Hemipancreatectomy (HPx) for the purpose of organ donation has been
associatedwitha25%riskofdevelopingabnormalglucosetoleranceordiabetesintheyearafter
surgery. Since 1997, the University of Minnesota has imposed criteria to prevent potential
donors with clinical features associated with an increased diabetes risk from undergoing HPx.
We recently assessed glucose tolerance in hemipancreatectomized donors selected since the
adoption of the new criteria to determine whether the risk of developing abnormal glucose
tolerance was reduced below the 25% rate previously demonstrated.
RESEARCH DESIGN AND METHODS — Individuals who underwent HPx for the
purpose of pancreas donation between 1997 and 2003 were contacted and interviewed about
theirhealthstatus.Thosenottakingdiabetesmedicationswereinvitedtoundergoanassessment
of their glucose tolerance.
RESULTS — Successful contact was made with 15 of 21 donors who underwent HPx during
this period. Two donors reported use of oral diabetic medications and were not studied further.
Of the remaining 13, 2 had impaired fasting glucose (fasting blood glucose 100–125 mg/dl), 1
had impaired glucose tolerance (2-h postglucose load blood glucose 140–199 mg/dl), and 3
displayed both. One donor met the diagnostic criteria for diabetes. Six donors had normal
glucose values.
CONCLUSIONS — Despite the use of stringent criteria to exclude those at risk for devel-
oping abnormalities in glucose metabolism, 43% of healthy humans who underwent HPx be-
tween 1997 and 2003 have impaired fasting glucose, impaired glucose tolerance, or diabetes on
follow-up. The current preoperative criteria are insufﬁcient to predict those who will develop
abnormal glucose metabolism after HPx.
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G
lycemic control has long been
known to play a critical role in the
development of the complications
of diabetes. Since the results of the Diabe-
tes Control and Complications Trial
(DCCT) ﬁrst demonstrated that intensive
efforts to lower glycemia resulted in a re-
duction in the rate at which subjects with
type 1 diabetes developed microvascular
complications(1),cliniciansandtheirpa-
tients have attempted to normalize glu-
cose control through many different
therapeutic modalities. Exogenous insu-
lin has been used to achieve target glyce-
mia almost universally in the treatment of
patients with type 1 diabetes, but the risk
of developing severe hypoglycemia has
become a limiting factor for many (2).
Pancreas transplantation offers an alter-
native for selected patients with diabetes
who seek to achieve normal levels of gly-
cemia without periodic hypoglycemia.
During 2004, 1,400 pancreas trans-
plantswereperformedintheU.S.(3).The
vast majority of these transplants were
done using deceased donor organs. How-
ever, some centers, including our own,
have considered using living donors in
situations in which improved outcomes
over the use of a deceased donor organ
might be expected. Such situations could
include the presence of a nondiabetic
HLA-identical sibling, a recipient with
high panel-reactive antibody levels, or as-
sociated morbidities that predict a high
risk of mortality while the recipient is on
the waiting list.
At the University of Minnesota, the
use of living donors in pancreas trans-
plantation dates back to 1977 (4). In this
procedure, the distal half of the pancreas
isremovedfromalivingdonorandplaced
within the pelvis of the diabetic recipient.
Although outcomes for the recipient are
at least equivalent to those achieved
with a deceased donor organ and per-
haps improved for those patients with
high panel-reactive antibody levels that
prevent an optimal tissue match (4),
25% of the donors were previously
found to have glucose intolerance or
frank diabetes (non–insulin-depen-
dent) 1 year after hemipancreatectomy
(HPx) (5). In addition, even donors
with normal glucose tolerance were
noted to experience a modest increase
in blood glucose and a reduction in in-
sulin and glucagon secretion 1 year
after HPx (6). Because of these ﬁndings,
the University of Minnesota changed
the criteria used to select hemipancreas
donors in 1997 to exclude those with
clinical or metabolic features that may
be associated with the future develop-
ment of diabetes.
In this report, we examine the meta-
bolic outcomes in hemipancreatecto-
mized donors selected because they
appeared to be at low risk for developing
diabetes. Our study was designed to test
thehypothesisthattheimplementationof
the revised University of Minnesota crite-
ria would reduce risk of development of
abnormal glucose tolerance to less than
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ous criteria (5). We hoped that our obser-
vations would be of beneﬁt to pancreas
transplant programs considering the de-
velopment of a living donor program.
Further study of this unique population
of healthy hemipancreatectomized hu-
mans also provides us with a rare oppor-
tunity to gain insight into the effect of
-cellmassreductiononthemaintenance
of normal glucose tolerance.
RESEARCH DESIGN AND
METHODS
Donor selection
InDecember1996,theUniversityofMin-
nesota pancreas transplant program re-
vised the selection criteria for living
hemipancreas donors to preclude those
believed to be at greatest risk for the de-
velopment of diabetes from undergoing
the procedure (7). The revised criteria are
shown in Table 1.
Operative procedure
TheoperativeprocedureforHPxhasbeen
described in detail elsewhere (4). The
procedureresultsinresectionofthedis-
tal pancreas where it overlies the portal
vein (50% resection), leaving the pan-
creatic head and proximal tail intact in
the donor. More recently, surgeons have
made the pancreas transection slightly to
the left of the portal vein, resulting in a
40% pancreatectomy.
Follow-up studies
In 2006, all donors who underwent HPx
between January 1997 and December
2003 were contacted by phone to ascer-
tain their willingness to participate in a
study. This contact was followed by a
written explanation of the study. All do-
nors contacted were interviewed on the
phone about their current health status.
Donors who were not taking diabetes
medications were asked to undergo the
metabolicevaluationdetailedbelow.This
protocol was approved by the University
of Minnesota Institutional Review Board,
and subjects gave written informed con-
sent before their participation.
The metabolic evaluation was done
after the donors had followed a diet con-
sisting of at least 150 g carbohydrate per
day for 3 days. On the day of the study,
donors presented to the University of
Minnesota General Clinical Research
Center or to a local clinic in the morning
after a 12-h fast. Oral glucose tolerance
tests were performed by administering
75 g glucose (Cardinal Health, McGaw
Park, IL) orally over a 5-min period.
Blood samples were obtained for later de-
termination of serum glucose levels at
10 and 5 min before glucose was ad-
ministeredandat30,60,90,and120min
after the administration of the glucose
load. Fasting samples were also obtained
for A1C, insulin, and anti-GAD antibody.
Serum glucose was measured on an Ana-
log glucose analyzer system (Analox In-
struments, Hammersmith, London,
U.K.). Serum insulin was measured using
chemiluminescence (Immulite 2000).
Samples for anti-GAD antibody levels
were analyzed using an immunoradio-
metric assay (Associated Regional and
University Pathologists, Salt Lake City,
UT)(8).Bloodsamplesobtainedinclinics
located away from the University of Min-
nesota were sent overnight to the Univer-
sity of Minnesota Medical Center for
analysis.
Data analysis
Unless otherwise indicated, results are
given as means  SD. The American Di-
abetes Association criteria for the diagno-
sis of diabetes, impaired glucose
tolerance, and impaired fasting glucose
(9) were used to categorize glucose toler-
ance in donors. The differences between
groupswereanalyzedbytwo-tailedstatis-
tics using the Mann-Whitney test for un-
paired data and the Wilcoxon signed-
ranktestorStudent’sttestforpaireddata.
Correlation was determined using the
Spearman rank order correlation coefﬁ-
cient. P  0.05 was considered statisti-
cally signiﬁcant.
RESULTS— Twenty-one individuals
underwent HPx for the purpose of organ
donation at the University of Minnesota be-
tween January 1997 and December 2003.
Preoperatively, 17 were noted to have nor-
mal fasting glucose values, normal glucose
tolerance, normal insulin secretory re-
sponses,andanunremarkablepersonaland
familymedicalhistory.Oneindividualwith
a mother who had type 2 diabetes, one in-
dividual with a BMI 27 kg/m
2, and three
individuals with a single glucose value be-
tween 150 and 199 mg/dl on the preopera-
tiveoralglucosetolerancetestwereallowed
to serve as hemipancreas donors because
theyperceivedtheirownriskofdonationto
be less than the recipient’s risk of foregoing
the transplant.
On follow-up, six donors could not
be located. On telephone interview, two
reported using a single antidiabetic agent
(metformininoneandpioglitazoneinthe
other). The remaining 13 donors com-
pleted the follow-up metabolic evalua-
tion. Abnormalities in glucose meta-
bolism were identiﬁed in 7 of 13 (54%)
reporting for follow-up evaluation (Fig.
1). Table 2 shows the preoperative and
postoperative results in the 13 hemipan-
createctomizeddonorswhowerestudied.
In the 13 donors who participated in
the metabolic evaluation, no differences
werenotedwithrespecttoageatdonation
(47  6 vs. 41  14 years) or months
since donation (60  10 vs. 55  12
months) between those with normal ver-
sus abnormal glucose tolerance at follow-
up. Despite the elevated postoperative
serum glucose levels in those with abnor-
malglucosetolerance,fastingseruminsu-
lin values were similar to those measured
in the donors with normal postoperative
glucosetolerance(5.33.0vs.6.43.6
U/ml, P  0.58). There was a trend to-
ward a higher BMI in the group with ab-
Table 1—Exclusion criteria used in selecting
human donors to undergo HPx for the pur-
pose of organ transplantation at the Univer-
sity of Minnesota, 1997–present
Absolute exclusion criteria
1. History of type 2 diabetes in any ﬁrst-
degree relative (parent, sibling)
2. History of gestational diabetes in the
proposed donor
3. Additional ﬁrst-degree relative with
type 1 diabetes (other than proposed
recipient)
4. BMI 27 kg/m
2
5. Age 50 years
6. Age of donor 10 years greater than
age of diagnosis of type 1 diabetes in
proband
7. Any glucose value 150 mg/dl during
an oral glucose tolerance test
8. A1C value 6%
9. Glucose disposal rate 1.0% during
intravenous glucose tolerance test
10. Presence of elevated titer of islet cell
autoantibodies (ICA)
Relative exclusion criteria
1. Basal, fasting insulin values 20 U/
ml (as marker of insulin resistance)
2. Acute insulin response to glucose,
arginine, or glucose potentiated
arginine 300% of basal insulin
3. Clinical evidence of insulin resistance
(e.g., polycystic ovary syndrome)
4. Evidence for 1 autoimmune
endocrine disorder (thyroid, adrenal,
pituitary, gonads)
Glucose intolerance/diabetes risk in HPx
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groupwithnormalglucosetoleranceboth
before (26.1  3.6 vs. 23.6  2.2 kg/m
2,
P  0.14) and after (26.4  4.4 vs.
23.5  2.4 kg/m
2, P  0.23) donation;
however, these differences were not sta-
tisticallysigniﬁcant.Anincreaseinweight
over time did not correlate with higher
fasting glucose values in these 13 donors
(Spearmanr
2
s0.21,P0.28).Allsub-
jects had immeasurable levels of GAD.
The subject who was selected despite a
family history of diabetes, the subject al-
lowed to donate despite having a BMI
27 kg/m
2, and two of the three subjects
who were allowed to donate despite
achieving a glucose value between 150
and 199 mg/dl on the preoperative oral
glucose tolerance tests showed abnormal
glucose tolerance on follow-up. HLA typ-
ing data are available for all 15 donors
contacted. Only two donors were het-
erozygous for the DRB1*3/4-
DQB1*0302 (DQ8) genotype that
confers higher risk for type 1 diabetes
(10). One of these donors had impaired
fasting glucose, and the other was taking
an oral antidiabetic agent on follow-up.
Table 3 summarizes the characteristics
andvariablesofthe13hemipancreatecto-
mized donors studied.
CONCLUSIONS — The purpose of
this study was to determine whether the
application of stringent metabolic criteria
duringtheselectionoflivingpancreasdo-
nors would reduce the risk of develop-
ment of abnormal glucose tolerance after
HPx to below the 25% rate reported pre-
viously (5). Whereas four of the current
donors who developed abnormalities in
glucose tolerance were allowed to donate
despite failing to meet all of the selection
criteria, ﬁve of the donors who met the
strict criteria developed to minimize the
risk of post-HPx disturbances in glucose
tolerance had either been given a diagno-
sis of diabetes by their primary physician
or had abnormal glucose tolerance on a
standard glucose tolerance test 3 to 10
years after organ donation. The preoper-
ative criteria, which are the gold standard
in the pretransplant workup for potential
Figure 1—Status of hemipancreatectomized human donors on follow-up. Human donors were
contacted between 3 and 10 years after undergoing HPx for the purpose of organ donation.
Table 2—Preoperative and postoperative results in 13 hemipancreatectomized donors studied
Donor
Fasting glucose (mg/dl) 2-h postprandial glucose (mg/dl) A1C (%) Fasting insulin (U/ml)
Before After Before After Before After Before After
1 82 110 98 167 NA 5.8 9 10
2 83 101 73 118 5.1 5.7 7 3
3 80 127 90 266 NA 6.3 4 11
4 NA 93 NA 122 NA 4.8 NA 9
5 85 92 NA 188 4.5 6.6 3 8
6 80 81 NA 101 NA 5.3 3 5
7 84 79 123 NA NA 5.5 NA 6
8 87 103 NA 152 5.7 6.3 6 1
9 93 92 69 81 5.1 5.6 9 8
10 83 94 NA 118 4.8 5.4 3 1
11 78 91 NA 138 5.0 5.7 3 3
12 88 109 NA NA 5.4 5.9 NA 7
13 76 116 56 145 5.5 5.8 1 5
Average 83  5 100  14* 77  17 155  62† 5.1  0.4 5.9  0.4* 4.8  2.8 5.5  3.6
Data are means  SD unless otherwise indicated. *P  0.01; †P  0.05. NA, not applicable.
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cessfulinidentifyingdonorsatriskforthe
development of diabetes and impaired
glucose tolerance after -cell mass reduc-
tion. Thus, the risk for postdonation glu-
cose intolerance cannot be completely
eliminated even with the application of
these narrow criteria. Our ﬁndings raise
concernsabouttheexpandeduseofliving
donors in pancreas and islet transplanta-
tion programs.
The metabolic effects of HPx for the
purpose of organ donation have been
studied previously. Bolinder et al. (12)
were the ﬁrst to demonstrate that fasting
bloodglucoseconcentrationswerehigher
after hemipancreas donation than they
werebeforesurgery.Thisobservationwas
quickly followed by that of Kendall et al.
(5) who noted that 25% of healthy indi-
viduals providing a hemipancreas to a
ﬁrst-degree relative with type 1 diabetes
developed abnormal glucose tolerance or
diabetes within 1 year of surgery. Subse-
quent work demonstrated that HPx is as-
sociated with reductions in glucose,
arginine, and glucose-potentiated argin-
ine-induced insulin secretion (6) as well
as an increase in serum proinsulin con-
centrations (13). -Cell mass reduction
has been presumed to be the cause of
these metabolic abnormalities after HPx.
This assumption is supported by recent
workinhumansinwhich-cellmasswas
found to be reduced in an autopsy study
of individuals with type 2 diabetes (14),
and the magnitude of the reduction ap-
peared to have a curvilinear relationship
with fasting glucose (15). These previous
studies, as well as the current study, sup-
port the hypothesis that a deﬁcit in -cell
mass contributes to the pathogenesis of
hyperglycemia and further emphasize the
need to maintain -cell mass to maintain
normal glucose tolerance.
Interesting new observations suggest
that a reduction in -cell mass may also
reduce glucose disposal in the peripheral
tissues (16). In dogs studied by Matvey-
enko et al. (16), a 50% pancreatectomy
resulted in impaired fasting glucose or
impairedglucosetolerance,areductionin
thepulsemassofglucose-inducedinsulin
secretion,adecreaseinhepaticinsulinex-
traction, and a 40% reduction in insulin-
stimulated glucose disposal. The ﬁndings
raise the provocative possibility that
-cell mass reduction may not only have
effectsoninsulinsecretionthatareimpor-
tantinthepathogenesisoftype2diabetes
but may also play a role in the impaired
insulin action present in this disorder in
thedog.Whether-cellmasshasaneffect
on insulin action in humans is not as
clear. Hemipancreatectomized human
donors have been found to have normal
insulin sensitivity as measured by the hy-
perinsulinemic-euglycemic clamp and by
the frequently sampled intravenous glu-
cose tolerance test (17), but the effect of
-cell mass reduction on the pulse mass
ofinsulinsecretionandonhepaticextrac-
tion has not been examined.
Why one group of donors went on to
develop abnormal glucose tolerance
whereas another group maintained nor-
mal glucose tolerance is not clear from
ourdata.Therewasatrendtowardhigher
BMIsamongthosewhodevelopedabnor-
mal glucose tolerance, but this difference
was not statistically signiﬁcant. In a pre-
vious study, obesity was more related to
the development of diabetes or glucose
intolerance in donors after HPx than fam-
ily history of type 2 diabetes or age (18).
In our cohort, the stringent criteria of
1997 recommended that no one with a
BMI 27 kg/m
2 be allowed to provide a
hemipancreas to a recipient with type 1
diabetes, although one donor with a BMI
of30.8waspermittedtoundergothepro-
cedure. Because nearly half of our rela-
tively lean cohort were found to have
abnormalglucosetoleranceonfollow-up,
it is possible that even BMI 27 kg/m
2 is
stilltoohightoensurethemaintenanceof
normal glucose homeostasis in the setting
of -cell mass reduction.
Nine of the donors in our group were
not biologically related to the recipient of
their hemipancreas. Five of these individ-
uals are known to have developed abnor-
mal glucose tolerance on follow-up. It is
interesting that the proportion of ﬁrst-
degreerelativesknowntohavedeveloped
diabetesorabnormalglucosetolerance(4
of 12) is actually lower than the propor-
tion in those unrelated to their recipient
(5of9),suggestingthatafamilyhistoryof
diabetes may not be predictive of abnor-
mal glucose tolerance after HPx.
The present study has certain limita-
tions. Six of the 21 donors operated on
between 1997 and 2003 were lost to fol-
low-up and as a result we lack a complete
descriptionoftheoutcomesinthispatient
group. However, even if all six of these
donors were found to have normal glu-
cose tolerance, 43% (9 of 21) of those un-
dergoing HPx during this period were
Table 3—Characteristics and variables of 13 hemipancreatectomized donors
Donor
Year of
surgery
Surgeon
(A, B, C, D, E)
Preoperative BMI
(kg/m
2)
ICA
(titer)
Related/
Unrelated
Time to follow-up
(months)
1 1999 A,B 31.8 4R 8 2
2 2000 C 27.3 4U 6 3
3 1998 C 20.2 4U 8 7
4 1998 C NA NA R 87
5 2000 B 26.0 4U 6 7
6 2000 C 21.6 NA U 70
7 1997 E 21.7 NA R 106
8 2000 D 27.2 4U 6 4
9 2002 E 26.1 4R 5 0
10 2000 D 22.4 4U 7 0
11 2000 C 23.1 NA R 75
12 1997 D 25.7 4 R 115
13 2003 D 23.8 4U 3 9
Average 24.7 75
ICA, islet cell antibody; NA, not applicable.
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on follow-up. Our conclusion that the
new criteria do not successfully exclude
subjects at risk for developing abnormal
glucose tolerance after HPx still stands.
All of these donors underwent a sur-
gical HPx, but it is unclear whether small
differences in technique among surgeons
could play a role in donor outcomes. De-
termining the exact percentage of islet tis-
sue removed is difﬁcult because of the
heterogeneous nature of the pancreas.
However,Robertsonetal.(18)foundthat
probable differences in -cell mass be-
tween donated and retained pancreatic
segmentsdidnotappeartoinﬂuenceclin-
ical outcomes.
In summary, our results indicate that
thedevelopmentofabnormalglucosetol-
erance is a risk inherent to HPx. Despite
the use of stringent criteria to exclude
those at risk for developing abnormalities
in glucose metabolism, 43% of healthy
humans who underwent HPx between
1997 and 2003 at the University of Min-
nesota (60% of those who reported for
examination) had impaired fasting glu-
cose, impaired glucose tolerance, or dia-
betes on follow-up. Given our inability to
accurately predict those who will develop
abnormalities in glucose tolerance and
the fact that, in most circumstances,
whole pancreas transplantation from a
deceased donor would be comparably ef-
fective(4),weconcludethatlivingdonors
should be used only in very special cir-
cumstances. Such circumstances may
arise in the presence of an HLA-identical
sibling or a recipient with high panel-
reactive antibody levels, which would
maketissuematchingverydifﬁcult,oras-
sociated morbidities that predict a high
risk of recipient mortality while on the
waiting list. As in the case of all living
organ donation, the donor should always
be expected to experience consequences.
In the future, preoperative genotyping
might be useful in excluding those poten-
tial donors with the greatest risk for de-
veloping diabetes, but until then our data
demonstrate that even subjects with nor-
mal preoperative metabolic characteris-
tics are at signiﬁcant risk of developing
abnormalities in glucose tolerance after
HPx.
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